Linked Life Data

16301833

Source:http://linkedlifedata.com/resource/pubmed/id/16301833

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-11-22
pubmed:abstractText
The anti-angiogenic agent bevacizumab (Avastin) has been rationally designed to target vascular endothelial growth factor (VEGF), a key mediator of tumor angiogenesis. Based on its limited roles in adults, VEGF inhibition using bevacizumab would be expected to have limited side effects. Furthermore, because its mechanism of action is different to that of standard chemotherapeutic agents, bevacizumab would not be expected to cause typical cytotoxic agent-related toxicity or to exacerbate the toxicity of concomitant chemotherapy. We have reviewed clinical trials published to date, primarily in metastatic colorectal cancer, and describe the safety profile of bevacizumab. The review focuses on hypertension, proteinuria, arterial thrombosis, effects on wound healing, bleeding and gastrointestinal (GI) perforation, which are the principal bevacizumab-related events seen in clinical trials. These events are for the most part mild to moderate in severity and clinically manageable (hypertension, proteinuria, minor bleeding) or occur uncommonly (wound healing complications, GI perforations and arterial thrombosis). The side-effect profile of bevacizumab makes it a suitable adjunct to standard chemotherapy in settings where efficacy has been demonstrated, and it is now approved for use in the USA, the European Union and other markets worldwide.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0030-2414
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2005 S. Karger AG, Basel.
pubmed:issnType
Print
pubmed:volume
69 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
25-33
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16301833-Angiogenesis Inhibitors, pubmed-meshheading:16301833-Antibodies, Monoclonal, pubmed-meshheading:16301833-Antibodies, Monoclonal, Humanized, pubmed-meshheading:16301833-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16301833-Clinical Trials as Topic, pubmed-meshheading:16301833-Colorectal Neoplasms, pubmed-meshheading:16301833-Fluorouracil, pubmed-meshheading:16301833-Hemorrhage, pubmed-meshheading:16301833-Humans, pubmed-meshheading:16301833-Hypertension, pubmed-meshheading:16301833-Incidence, pubmed-meshheading:16301833-Intestinal Perforation, pubmed-meshheading:16301833-Leucovorin, pubmed-meshheading:16301833-Proteinuria, pubmed-meshheading:16301833-Thrombosis, pubmed-meshheading:16301833-Vascular Endothelial Growth Factor A, pubmed-meshheading:16301833-Wound Healing
pubmed:year
2005
pubmed:articleTitle
Managing patients treated with bevacizumab combination therapy.
pubmed:affiliation
Arizona Cancer Center, Greater Phoenix Area, Scottsdale, Ariz. 85258, USA. msgordon@u.arizona.edu
pubmed:publicationType
Journal Article, Review